Brazil's Anvisa recalls irregular slimming pen substances; retatrutida unapproved

Brazil's health regulator Anvisa ordered a recall of batches of tirzepatide and retatrutide stored irregularly, with retatrutide not yet approved for use. The action targets supply chain compliance rather than safety signals, but underscores regulatory scrutiny of the weight-loss drug market. Impact is limited to Brazil and specific batches.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works